If you have been reading about synthetic peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-05. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
== Development == The mod was developed by Adrian Finol in 2000. Finol created a unique mod that focused on intense, fast paced game-play that set it apart from other total conversion mods. Finol's goal was to create an online first person shooter that was more 'team based' than Counter-Strike, with bonuses for acting with team mates. Several versions were created under Finol's lead, each one adding new features and tweaking the game-play. In late 2001, Finol handed the FLF torch to Dave Dynerman so that he could start a new career with Valve Corporation. Several key contributors of the original FLF team now work for Valve. Under the lead of Dynerman, FLF went through several upgrades, resulting in even more versions. Dynerman went on to join Raven Software early in 2003 and Tony Sergi took over as the lead coder. Sergi created many versions for FLF, although not all became public. As the release of Half-Life 2 approached Sergi, along with the development team, faced a difficult decision. A great deal of time and work from all aspects had gone into the most recent unreleased versions of FLF (1.9 and Defiance), but the mod would have a hard time competing with other mods that were moving to the Half-Life 2 Source engine. Faced with a declining player base and only a handful of members left, the development team with real lifetime constraints for some, put further FLF work on hold.
=== Phase 3 === Aroxybutynin/atomoxetine (AD-109; atomoxetine/aroxybutynin) – combination of aroxybutynin (muscarinic acetylcholine receptor antagonist/anticholinergic) and atomoxetine (norepinephrine reuptake inhibitor) [1], Mazdutide (IBI-362; LY-3305677; OXM-3) – glucagon-like peptide-1 (GLP-1) receptor agonist and glucagon receptor agonist – obesity-related sleep apnea [2] Orforglipron (LY-3502970; OWL-833) – glucagon-like peptide-1 (GLP-1) receptor agonist – obesity-related sleep apnea [3] Retatrutide (LY-3437943) – glucagon-like peptide-1 (GLP-1) receptor agonist, glucagon receptor agonist, and gastric inhibitory polypeptide (GIP) receptor agonist – obesity-related sleep apnea [4]
[...] The staffs concerned must have planned this for months – they had to formulate an overall operations plan, to move in the stocks necessary for the battle, to plan and to allocate the aviation resources for the deployment of troops to Georgia and other logistic capabilities, to produce a target list for the air force, and so on. [...] the scope and intensity of their attack exceeded the forecasts made by the Georgian leadership and the Western countries. The Russians achieved a strategic advantage by way of using the element of surprise." He pointed out that most of the Russian military units that fought in Georgia belonged to the North Caucasus Military District, whose capabilities surpass every other Russian districts. In June 2009, Svante Cornell wrote, "Many scholars have now shown Russia's invasion of Georgia had been long in the planning, premeditated and intended to deal a mortal blow to what Moscow saw as western encroachment in its backyard. Whatever mistakes the Georgian government may have made in being lured into war, there is little doubt Moscow provoked the conflict to bully its neighbors into submission." According to Cornell, the Kremlin spent millions in an international information campaign to blame Georgia for the war; however, there is evidence, including some in Russian media, that Russia actually started the war.
=== Nervous system repair === Spinal cord injuries are one of the most common traumas brought into veterinary hospitals. Spinal injuries occur in two ways after the trauma: the primary mechanical damage, and in secondary processes, like inflammation and scar formation, in the days following the trauma. These cells involved in the secondary damage response secrete factors that promote scar formation and inhibit cellular regeneration. Mesenchymal stem cells that are induced to a neural cell fate are loaded onto a porous scaffold and are then implanted at the site of injury. The cells and scaffold secrete factors that counteract those secreted by scar forming cells and promote neural regeneration. Eight weeks later, dogs treated with stem cells showed immense improvement over those treated with conventional therapies. Dogs treated with stem cells were able to occasionally support their own weight, which has not been seen in dogs undergoing conventional therapies. In a study to evaluate the treatment of experimentally induced MS in dogs using laser activated non-expanded adipose derived stem cells. The results showed amelioration of the clinical signs over time confirmed by the resolution of the previous lesions on MRI. Positive migration of the injected cells to the site of lesion, increased remyelination detected by Myelin Basic Proteins, positive differentiation into Olig2 positive oligodendrocytes, prevented the glial scar formation and restored axonal architecture. Treatments are also in clinical trials to repair and regenerate peripheral nerves.
Sources: en.wikipedia.org
Kazuaki Kiriya's action-thriller Last Knights was Freeman's first film of 2015, starring opposite Clive Owen. The plot centers on a band of warriors who seek to avenge the loss of their master at the hands of a corrupt minister. Reviews were largely underwhelming; Sara Stewart of New York Post called it "bloody bad", adding: "Once-proud box office names are its first casualties." Freeman next joined the cast of Ted 2, a comedy sequel to Ted, directed by Seth MacFarlane. The story follows the talking teddy bear Ted as he fights for civil rights in order to be recognized as a person. Freeman portrays Patrick Meighan, a highly respected civil rights attorney. A television series, Madam Secretary, also occupied Freeman's time. He played Chief Justice Frawley of the United States Supreme Court in a recurring role in the series. He and his producing partner Lori McCreary were executive producers. Freeman directed the first episode; McCreary remarked of his directing style, "What's riveting is that he can achieve a complete tonal change in performance with the least amount of direction ... Everybody behaves better when Morgan is there ... but he's very fun." At the end of 2015, Freeman played a U.S. senator in the thriller Momentum. Reprising his role as Allan Trumbull, Freeman appeared in London Has Fallen, the 2016 sequel to Olympus Has Fallen. The film follows a plot to assassinate the world leaders of the G7 as they attend the British Prime Minister's funeral in London, as well as Secret Service agent Mike Banning's efforts to protect U.S.
=== Non-human infection === Treponema pallidum has been found in non-human primates in multiple different geographical regions. In Tanzania specifically, T. pallidum geographical distribution closely aligns with the distribution of yaws in humans. The most common strains in NHPs are T. p. pertenue and T. p.endemicum. It is unclear however whether or not these NHP strains can naturally infect humans, but flies have been proposed as possible vectors in an alternative transmission route. Clinically, these infections range from asymptomatic to severe skin ulceration that affect the face or genitalia in these primates. Infection of NHPs is largely reliant on ecological patterns, behaviors, and interactions between the species. There are no current treatments available for infected NHPs.
In cell biology, single-cell analysis and subcellular analysis refer to the study of genomics, transcriptomics, proteomics, metabolomics, and cell–cell interactions at the level of an individual cell, as opposed to more conventional methods which study bulk populations of many cells. The concept of single-cell analysis originated in the 1970s. Before the discovery of heterogeneity, single-cell analysis mainly referred to the analysis or manipulation of an individual cell within a bulk population of cells under the influence of a particular condition using optical or electron microscopy. Due to the heterogeneity seen in both eukaryotic and prokaryotic cell populations, analyzing the biochemical processes and features of a single cell makes it possible to discover mechanisms which are too subtle or infrequent to be detectable when studying a bulk population of cells; in conventional multi-cell analysis, this variability is usually masked by the average behavior of the larger population. Technologies such as fluorescence-activated cell sorting allow the precise isolation of selected single cells from complex samples, while high-throughput single-cell partitioning technologies enable the simultaneous molecular analysis of hundreds or thousands of individual unsorted cells; this is particularly useful for the analysis of variations in gene expression between genotypically identical cells, allowing the definition of otherwise undetectable cell subtypes.
Sabizabulin is an investigational new drug that is being evaluated for the treatment of castration-resistant prostate cancer and in SARS-CoV-2 (COVID-19) infections. It is a tubulin polymerization inhibitor. Sabizabulin is chemical compound from the group of indole and imidazole derivatives that was first reported in 2012 by Dalton, Li, and Miller.
=== Individual reactions === The removal of the blue checkmark and Twitter Blue have sparked controversy. Actress Alyssa Milano added to her Twitter profile that she would not be paying for Twitter Blue. The Twitter account for Elmo tweeted that, "Elmo will miss you, little blue check mark". The blue checkmark has also caused crosscurrents between Twitter users, with technology journalist Joanna Stern writing that she "likes editing tweets", and appears to have distanced herself from the blue checkmark. Morning Consult journalist Bobby Blanchard asked Twitter to remove his blue checkmark. Other personalities and entities appeared confused as to why their blue checkmarks appeared despite not subscribing to Twitter Blue, such as journalist Maggie Haberman, actors Ben Schwartz and Elijah Wood, astrophysicist Neil deGrasse Tyson, and the Massachusetts Institute of Technology. The Twitter account for the Auschwitz-Birkenau State Museum clarified that it had not paid for Twitter Blue either. Model Chrissy Teigen compared her blue checkmark to the film It Follows (2014) and was able to get hers removed by changing her username, telling speechwriter Jon Favreau. Favreau later stated that he believed Musk was "capricious" in his actions and did not want to be potentially suspended for unverifying his account. Likewise, stand-up comedian and actor Patton Oswalt changed his username to remove his blue checkmark. dril, part of Twitter's secretive list of users to promote and of "Weird Twitter", removed his blue checkmark by changing his display name to "slave to Woke".
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.